APA (7th ed.) Citation

CL, F., S, S., B, H., S, D., T, H., M, B., . . . DW, S. (2025). Prognostic biomarkers in MCL: Insights from the SHINE trial on the impact of MCL35 score and TP53 mutation status. Blood, 145(25), 3052. https://doi.org/10.1182/blood.2024026003

Chicago Style (17th ed.) Citation

CL, Freeman, Srinivasan S, Hodkinson B, Deshpande S, Henninger T, Boyle M, Wang ML, Dreyling M, and Scott DW. "Prognostic Biomarkers in MCL: Insights from the SHINE Trial on the Impact of MCL35 Score and TP53 Mutation Status." Blood 145, no. 25 (2025): 3052. https://doi.org/10.1182/blood.2024026003.

MLA (9th ed.) Citation

CL, Freeman, et al. "Prognostic Biomarkers in MCL: Insights from the SHINE Trial on the Impact of MCL35 Score and TP53 Mutation Status." Blood, vol. 145, no. 25, 2025, p. 3052, https://doi.org/10.1182/blood.2024026003.